Zacks Research Has Bearish Forecast for Zoetis Q2 Earnings

Zoetis Inc. (NYSE:ZTS - Free Report) - Investment analysts at Zacks Research dropped their Q2 2025 earnings per share estimates for Zoetis in a report released on Monday, May 26th. Zacks Research analyst E. Bagri now expects that the company will post earnings of $1.59 per share for the quarter, down from their previous forecast of $1.60. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis' Q1 2027 earnings at $1.66 EPS and FY2027 earnings at $7.25 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm's revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.38 earnings per share.

A number of other research firms have also commented on ZTS. Stifel Nicolaus reduced their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Barclays increased their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Trading Up 0.9%

Shares of NYSE ZTS traded up $1.57 during mid-day trading on Wednesday, hitting $168.71. 5,467,815 shares of the company traded hands, compared to its average volume of 2,533,285. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a market capitalization of $75.11 billion, a price-to-earnings ratio of 30.84, a PEG ratio of 2.78 and a beta of 0.94. The business has a 50 day moving average of $156.65 and a two-hundred day moving average of $164.63.

Hedge Funds Weigh In On Zoetis

Several hedge funds have recently bought and sold shares of the business. Norges Bank acquired a new position in shares of Zoetis during the 4th quarter valued at about $824,321,000. Nuveen LLC bought a new stake in Zoetis during the first quarter worth approximately $616,375,000. Wellington Management Group LLP grew its holdings in Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares during the last quarter. Sarasin & Partners LLP acquired a new position in Zoetis during the first quarter valued at approximately $339,111,000. Finally, Mackenzie Financial Corp lifted its stake in shares of Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after buying an additional 1,782,110 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.18% of the company's stock.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. Zoetis's dividend payout ratio is 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.